The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients
Abstract
The lag between β‐amyloid (Aβ) deposition and neurodegeneration in Alzheimer's disease (AD) suggests that age‐dependent factors are involved in the pathogenesis. Racemization of Ser and Asp in Aβ is a typical age‐dependent modification in AD. We have shown recently that Aβ1–40 racemized at Ser 26 ([D‐Ser26]Aβ1–40) is soluble and non‐toxic to neuronal cells, but is easily converted by brain proteases to truncated toxic fragments, [D‐Ser26]Aβ25–35/40. Furthermore, [D‐Ser26]Aβ1–40 in vivo, produced a drastic and synergistic neuronal loss by enhancing the excitotoxicity when co‐injected into rat hippocampus with ibotenic acid, an excitatory amino acid, suggesting an in vivo conversion of non‐toxic [D‐Ser 26]Aβ1–40 to toxic fragments including [D‐Ser 26]Aβ25–35/40. In this study, we further investigated the mechanism behind the in vivo neuronal loss by [D‐Ser 26]Aβ1–40 and ibotenic acid in rats, and also searched for the presence of [D‐Ser 26]Aβ25–35/40 antigens in AD brains. Quantitative analyses of the damaged area indicate clearly that non‐toxic [D‐Ser 26]Aβ1–40 caused as much neurodegeneration as toxic [D‐Ser 26]Aβ25–35/40. MK‐801, an NMDA receptor antagonist, completely inhibited the neurodegeneration. The immunohistochemical analyses using anti‐[D‐Ser 26]Aβ25–35/40‐specific antibodies demonstrated the presence of [D‐Ser 26]Aβ25–35/40 antigens in senile plaques and in degenerating hippocampal CA1 neurons in AD brains, but not in age‐matched control brains. These results strengthen our hypothesis that soluble [D‐Ser 26]Aβ1–40, possibly produced during aging, is released from plaques and converted by proteolysis to toxic [D‐Ser 26]Aβ25–35/40, which damage hippocampal CA1 neurons by enhancing excitotoxicity in AD. This may account for the lag between Aβ deposition and neurodegeneration in AD. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“In vitro toxicity of fibrillar A to neuronal cells was demonstrated by many investigators (Yankner et al., 1990; Pike et al., 1993; Kaneko et al., 1995, 2001).”
MethodOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799
Chui, D.-H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O., Suzuki, H., Araki, W., Inoue, H., Shirotani, K., et al. (1999) · Nature Medicine · doi:10.1038/8438 · Cited by 364
Cited by
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 571
Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2015) · Medical Principles and Practice · doi:10.1159/000369101 · Cited by 537
Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats
Arancibia, S., Silhol, M., Moulière, F., Meffre, J., Höllinger, I., Maurice, T., & Tapia-Arancibia, L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.012 · Cited by 317
Allaman, I., Gavillet, M., Bélanger, M., Laroche, T., Viertl, D., Lashuel, H. A., & Magistretti, P. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5098-09.2010 · Cited by 278
Central role of glucocorticoid receptors in Alzheimer's disease and depression
Canet, G., Chevallier, N., Zussy, C., Desrumaux, C., & Givalois, L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00739 · Cited by 106
Metadata
- Authors
- Kubo, T., Nishimura, S., Kumagae, Y., & Kaneko, I.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2002-10-18
- Volume
- 70
- Issue
- 3
- Pages
- 474-483
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2082317154
- Cited by
- 250
- References
- 8
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients. https://app.cochat.ai/papers/10.1002/jnr.10391
- The paper
- Kubo, T., Nishimura, S., Kumagae, Y., & Kaneko, I. (2002). In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.10391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.